GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » Beneish M-Score

Vycor Medical (Vycor Medical) Beneish M-Score : -2.75 (As of May. 31, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.75 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vycor Medical's Beneish M-Score or its related term are showing as below:

VYCO' s Beneish M-Score Range Over the Past 10 Years
Min: -6.96   Med: -4.66   Max: -2.54
Current: -2.75

During the past 13 years, the highest Beneish M-Score of Vycor Medical was -2.54. The lowest was -6.96. And the median was -4.66.


Vycor Medical Beneish M-Score Historical Data

The historical data trend for Vycor Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vycor Medical Beneish M-Score Chart

Vycor Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.75 -5.91 -5.79 -3.27 -2.64

Vycor Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.58 -2.65 -2.57 -2.64 -2.75

Competitive Comparison of Vycor Medical's Beneish M-Score

For the Medical Devices subindustry, Vycor Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vycor Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vycor Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vycor Medical's Beneish M-Score falls into.



Vycor Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vycor Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2115+0.528 * 0.9968+0.404 * 0.8617+0.892 * 1.1315+0.115 * 1.1622
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8324+4.679 * -0.123839-0.327 * 0.9836
=-2.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.24 Mil.
Revenue was 0.337 + 0.308 + 0.309 + 0.483 = $1.44 Mil.
Gross Profit was 0.3 + 0.266 + 0.276 + 0.443 = $1.29 Mil.
Total Current Assets was $0.59 Mil.
Total Assets was $0.97 Mil.
Property, Plant and Equipment(Net PPE) was $0.38 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.06 Mil.
Selling, General, & Admin. Expense(SGA) was $1.21 Mil.
Total Current Liabilities was $4.26 Mil.
Long-Term Debt & Capital Lease Obligation was $0.23 Mil.
Net Income was -0.031 + -0.093 + -0.052 + 0.068 = $-0.11 Mil.
Non Operating Income was 0.004 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was 0.002 + 0.006 + -0.013 + 0.013 = $0.01 Mil.
Total Receivables was $0.18 Mil.
Revenue was 0.361 + 0.271 + 0.31 + 0.328 = $1.27 Mil.
Gross Profit was 0.33 + 0.234 + 0.268 + 0.3 = $1.13 Mil.
Total Current Assets was $0.52 Mil.
Total Assets was $0.84 Mil.
Property, Plant and Equipment(Net PPE) was $0.31 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.06 Mil.
Selling, General, & Admin. Expense(SGA) was $1.29 Mil.
Total Current Liabilities was $3.79 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.244 / 1.437) / (0.178 / 1.27)
=0.169798 / 0.140157
=1.2115

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.132 / 1.27) / (1.285 / 1.437)
=0.891339 / 0.894224
=0.9968

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.588 + 0.375) / 0.969) / (1 - (0.52 + 0.309) / 0.835)
=0.006192 / 0.007186
=0.8617

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.437 / 1.27
=1.1315

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.06 / (0.06 + 0.309)) / (0.061 / (0.061 + 0.375))
=0.162602 / 0.139908
=1.1622

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1.214 / 1.437) / (1.289 / 1.27)
=0.844816 / 1.014961
=0.8324

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.231 + 4.256) / 0.969) / ((0.145 + 3.786) / 0.835)
=4.630547 / 4.707784
=0.9836

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.108 - 0.004 - 0.008) / 0.969
=-0.123839

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vycor Medical has a M-score of -2.75 suggests that the company is unlikely to be a manipulator.


Vycor Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Vycor Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vycor Medical (Vycor Medical) Business Description

Traded in Other Exchanges
N/A
Address
951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487
Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.
Executives
David Cantor director, officer: President 1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell director, officer: Chairman ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou director, 10 percent owner, officer: Chief Executive Officer C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush director C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti director C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd 10 percent owner PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical (Vycor Medical) Headlines